gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2021-31-1-47-53gastro-j-538Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИNATIONAL COLLEGE OF GASTROENTEROLOGY, HEPATOLOGYСовременные возможности применения пантопразола для лечения и профилактики гастроэнтерологических заболеванийCurrent Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseaseshttps://orcid.org/0000-0002-1395-9566ШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифософского.

119435, Москва, Погодинская ул., д. 1, стр. 1.

Arkadiy A. Sheptulin — Dr. Sci (Med.), Professor, Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).

119435, Moscow, Pogodinskaya str., 1/1.

arkalshep@gmail.comhttps://orcid.org/0000-0002-5116-2144КардашеваС. С.KardashevaS. S.

Кардашева Светлана Станославовна — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифософского.

119435, Москва, Погодинская ул., д. 1, стр. 1.

Svetlana S. Kardasheva — Cand. Sci (Med.), Associate Professor, Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).

119435, Moscow, Pogodinskaya str., 1/1.

svetlanakardasheva@gmail.comhttps://orcid.org/0000-0002-6154-8163КурбатоваА. А.KurbatovaA. A.

Курбатова Анастасия Александровна — кандидат медицинских наук, ассистент кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифософского.

119435, Москва, Погодинская ул., д. 1, стр. 1.

Anastasya A. Kurbatova — Cand. Sci (Med.), Assistant, Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).

119435, Moscow, Pogodinskaya str., 1/1.

maxnastia@mail.ruПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет) Министерства здравоохранения Российской ФедерацииРоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation2021070220213114753Copyright © Шептулин А.А., Кардашева С.С., Курбатова А.А., 20212021Шептулин А.А., Кардашева С.С., Курбатова А.А.Sheptulin A.A., Kardasheva S.S., Kurbatova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/538Цель обзора

Цель обзора: показать современные возможности применения пантопразола для лечения и профилактики заболеваний верхних отделов желудочно-кишечного тракта (ЖКТ).

Основные положения

Основные положения. Пантопразол широко применяется для лечения гастроэзофагеальной рефлюксной болезни, язвенной болезни, синдрома Золлингера — Эллисона, эрадикации Helicobacter pylori. Пантопразол в наименьшей степени блокирует изофермент CYP2C19, участвующий в метаболизме многих лекарственных препаратов. Особенности фармакокинетики пантопразола определяют меньшую выраженность лекарственного взаимодействия по сравнению с другими ингибиторами протонной помпы, что делает возможным его назначение для профилактики желудочно-кишечных кровотечений пациентам, получающим двойную антитромбоцитарную терапию. В период пандемии новой коронавирусной инфекции (COVID-19) для терапии и профилактики кислотозависимых заболеваний верхних отделов ЖКТ необходимо использование ИПП, имеющих минимальный риск лекарственных взаимодействий, например пантопразол. Пантопразол хорошо переносится больными и отличается низкой частотой побочных эффектов.

Заключение

Заключение. Пантопразол представляется одним из оптимальных ИПП по соотношению эффективности, безопасности и приверженности к лечению на основании клинических исследований лечения и профилактики гастроэнтерологических заболеваний, систематических обзоров и метаанализов.

Aim

Aim. An outline of the current potential of pantoprazole in treatment and prevention of upper gastrointestinal diseases.

Key points

Key points. Pantoprazole is widely applied in gastroesophageal reflux, peptic ulcer disease, Zollinger—Ellison syndrome and for Helicobacter pylori eradication. It minimally inhibits the CYP2C19 isoenzyme involved in the metabolism of many drugs. Pharmacokinetics of pantoprazole conditions a weaker drug interaction compared to other proton pump inhibitors (PPIs), which enables its use for gastrointestinal bleeding prevention in patients receiving dual antiplatelet therapy. The new coronaviral pandemic of COVID-19 urges the selection of PPIs that minimise the drug interference, such as pantoprazole, in therapy and prevention of acid-related upper gastrointestinal diseases. Pantoprazole has a good tolerance and low side effect rate.

Conclusion

Conclusion. Pantoprazole is considered among optimal PPIs for efficacy, safety and adherence on the basis of clinical trials for treatment and prevention of gastrointestinal diseases, systematic reviews and meta-analyses.

пантопразолязвенная болезньгастроэзофагеальная рефлюксная болезньжелудочнокишечные кровотеченияpantoprazolepeptic ulcergastroesophageal refluxgastrointestinal bleeding Conflict of interest: the publication was supported by the KRKA companyПубликация выполнена при поддержке компании «КРКА».The publication was supported by the KRKA company.ReferencesSachs G., Shin J.M. The basis of differentiation of PPIs. Drugs today. 2004;40 (suppl.A):9-14. PMID: 15190382Sachs G., Shin J.M. The basis of differentiation of PPIs. Drugs today. 2004;40 (suppl.A):9-14. PMID: 15190382Vacyshyn B.R., Thompson A.B.R. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion. 2002;66(2):67-78. DOI: 10.1159/000065588Vacyshyn B.R., Thompson A.B.R. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion. 2002;66(2):67-78. DOI: 10.1159/000065588Jonaitis P., Jonaitis L., Kupcinskas J. Role of genetic polymorphisms of cytochrome P450 2C19 in pantoprazole metabolism and pantoprazole-based Helicobacter pylori eradication regimens. Curr. Drug Metab. 2020;21(11):830-7. DOI: 10.2174/1389200221666200514081442Jonaitis P., Jonaitis L., Kupcinskas J. Role of genetic polymorphisms of cytochrome P450 2C19 in pantoprazole metabolism and pantoprazole-based Helicobacter pylori eradication regimens. Curr. Drug Metab. 2020;21(11):830-7. DOI: 10.2174/1389200221666200514081442Wedemeyer R.-S., Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201-11. DOI: 10.1007/s40264-014-0144-0Wedemeyer R.-S., Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201-11. DOI: 10.1007/s40264-014-0144-0Angiolillo D.J., Gibson C.M., Cheng S., Ollier C., Nicolas O., Bergougnan L., et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. DOI: 10.1038/clpt.2010.219Angiolillo D.J., Gibson C.M., Cheng S., Ollier C., Nicolas O., Bergougnan L., et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. DOI: 10.1038/clpt.2010.219Choi Y.J. Kim N., Jang I.J., Cho J.Y., Nam R.H., Park J.H., et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: A randomized controlled trial in Korea. Gut Liver. 2017;11(4):504-11. DOI: 10.5009/gnl16352Choi Y.J. Kim N., Jang I.J., Cho J.Y., Nam R.H., Park J.H., et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: A randomized controlled trial in Korea. Gut Liver. 2017;11(4):504-11. DOI: 10.5009/gnl16352Matheus S., Reid A., Tian C., Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol. 2010;3:11-6. DOI: 10.2147/ceg.s6355Matheus S., Reid A., Tian C., Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol. 2010;3:11-6. DOI: 10.2147/ceg.s6355Remes-Troche J.M., Sobrino-Cossio S., Soto-Peres J.C., Teramoto-Matsubara O., Morale-Arambula M., Orozko-Gamiz A., et al. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. Clin Drug Investig. 2014;34(2):83-93.. DOI: 10.1007/s40261-013-0135-4Remes-Troche J.M., Sobrino-Cossio S., Soto-Peres J.C., Teramoto-Matsubara O., Morale-Arambula M., Orozko-Gamiz A., et al. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. Clin Drug Investig. 2014;34(2):83-93.. DOI: 10.1007/s40261-013-0135-4Morales-Filho J.P., Pedroso M., Quigley E.M.M., PAMES Study Group. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. Aliment Pharmacol Ther. 2014;39(1):47-56. DOI: 10.1111/apt.12540Morales-Filho J.P., Pedroso M., Quigley E.M.M., PAMES Study Group. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. Aliment Pharmacol Ther. 2014;39(1):47-56. DOI: 10.1111/apt.12540Dabrowski A., Stabuc D., Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease — PAN-STAR. Prz Gastroenterol. .2018; 13(1): 6-15. DOI: 10.5114/pg.2018.74556Dabrowski A., Stabuc D., Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease — PAN-STAR. Prz Gastroenterol. .2018; 13(1): 6-15. DOI: 10.5114/pg.2018.74556Lopes-Alvarenga J.C., Orr W., Vargas-Romero J.A., Remes-Troche J.M., Morales-Arambula M., Soto-Peres J.C., et al. Relief of night-time symptoms associated with gastroesophageal reflux disease following 4 weeks of treatment with pantoprazole magnesium: The Mexican gastroesophageal reflux disease working group. J Neuro-gastroenterol Motil. 2014;20(1):64-73. DOI: 10.5056/jnm.2014.20.1.64Lopes-Alvarenga J.C., Orr W., Vargas-Romero J.A., Remes-Troche J.M., Morales-Arambula M., Soto-Peres J.C., et al. Relief of night-time symptoms associated with gastroesophageal reflux disease following 4 weeks of treatment with pantoprazole magnesium: The Mexican gastroesophageal reflux disease working group. J Neuro-gastroenterol Motil. 2014;20(1):64-73. DOI: 10.5056/jnm.2014.20.1.64Kindt S., Imschoot J., Tack J. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. Dis Esophagus. 2011;24( 8):531-7. DOI: 10.1111/j.1442-2050.2011.01189.xKindt S., Imschoot J., Tack J. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. Dis Esophagus. 2011;24( 8):531-7. DOI: 10.1111/j.1442-2050.2011.01189.xLi M.-J., Li Q., Sun M., Liu L.-Q. Comparative effectiveness and acceptability. Od the FDA-licensed proton-pump inhibitors for erosive esophagitis. A PRISMA-compliant network meta-analysis. Medicine. 2017;96(39):e8120. DOI: 10.1097/MO0000000000008120Li M.-J., Li Q., Sun M., Liu L.-Q. Comparative effectiveness and acceptability. Od the FDA-licensed proton-pump inhibitors for erosive esophagitis. A PRISMA-compliant network meta-analysis. Medicine. 2017;96(39):e8120. DOI: 10.1097/MO0000000000008120Lechien J.R., Bobin F., Muls V., Eisendrath P., Horoi M., Thill M-P., et al. Gastroesophageal reflux in laryngopharyngeal reflux patients: Clinical features and therapeutic response. Laryngoscope. 2020;130(8):E479-89. DOI: 10.1002/lary.28482Lechien J.R., Bobin F., Muls V., Eisendrath P., Horoi M., Thill M-P., et al. Gastroesophageal reflux in laryngopharyngeal reflux patients: Clinical features and therapeutic response. Laryngoscope. 2020;130(8):E479-89. DOI: 10.1002/lary.28482Hu Z.-H., Shi A.-M., Hu D.-M., Bao J.-J. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials. Saudi J Gastroenterol. 2017;23(1):11-9. DOI: 10.4103/1319-3767.199117Hu Z.-H., Shi A.-M., Hu D.-M., Bao J.-J. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials. Saudi J Gastroenterol. 2017;23(1):11-9. DOI: 10.4103/1319-3767.199117Zhang J., Ge L., Hill M., Liang Y., Xie J., Cui D., et al. Standard-dose proton pump inhibitors in the initial non-eradication treatment of duodenal ulcer: systematic review, network meta-analysis, and cost-effectiveness analysis. Front Pharmacol. 2019;9:1512. DOI: 10.3389/fphar.2018.01512Zhang J., Ge L., Hill M., Liang Y., Xie J., Cui D., et al. Standard-dose proton pump inhibitors in the initial non-eradication treatment of duodenal ulcer: systematic review, network meta-analysis, and cost-effectiveness analysis. Front Pharmacol. 2019;9:1512. DOI: 10.3389/fphar.2018.01512McNicholl A.G., Bordin D.S., Lucendo A., Fadeen-ko G., Castro M., Voynovan I., et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol. 2020;18(1):89-98. DOI: 10.1016/j.cgh.2019.03.048McNicholl A.G., Bordin D.S., Lucendo A., Fadeen-ko G., Castro M., Voynovan I., et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol. 2020;18(1):89-98. DOI: 10.1016/j.cgh.2019.03.048Kan L.-D., Chen J., Huang Y.-T., Qin Y., Yu X.-L., Fang H.-M., et al. Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication. Clin Exp Med. 2020 Nov;20(4):609-14. DOI: 10.1007/s10238-020-00643-2Kan L.-D., Chen J., Huang Y.-T., Qin Y., Yu X.-L., Fang H.-M., et al. Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication. Clin Exp Med. 2020 Nov;20(4):609-14. DOI: 10.1007/s10238-020-00643-2Van Rensburg J., Cheer S. Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding. Clin Med Insights Gastroenterol. 2012;5:51-60. DOI: 10.4137/CGast.S9893Van Rensburg J., Cheer S. Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding. Clin Med Insights Gastroenterol. 2012;5:51-60. DOI: 10.4137/CGast.S9893Motiei A., Sebghatolahi V. Efficacy comparison of divided and infusion untravenous pantoprazole methods after endoscopic therapy in patients with acute gastrointestinal bleeding. Adv Biomed Res. 2017;6:120. DOI: 10.4103/abr.abr_59_16Motiei A., Sebghatolahi V. Efficacy comparison of divided and infusion untravenous pantoprazole methods after endoscopic therapy in patients with acute gastrointestinal bleeding. Adv Biomed Res. 2017;6:120. DOI: 10.4103/abr.abr_59_16Barletta J.F., Buckley M.S., MacLaren R. The SUP-ICU trial: does it confirm or condemn the practice of stress ulcer prophylaxis? Hosp Pharm. 2020;55 (2):96-101. DOI: 10.1177/0018578719867687Barletta J.F., Buckley M.S., MacLaren R. The SUP-ICU trial: does it confirm or condemn the practice of stress ulcer prophylaxis? Hosp Pharm. 2020;55 (2):96-101. DOI: 10.1177/0018578719867687Granholm A., Marker S., Krag M., Zampieri F.G., Thorsen-Meyer H.-C., Kaas-Hansen B.S., et al. Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial. Intensive Care Med. 2020;46(4):717-26. DOI: 10.1007/s00134-019-05903-8Granholm A., Marker S., Krag M., Zampieri F.G., Thorsen-Meyer H.-C., Kaas-Hansen B.S., et al. Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial. Intensive Care Med. 2020;46(4):717-26. DOI: 10.1007/s00134-019-05903-8Wei P., Zhang Y.-G., Ling L., Tao Z.-Q,. Ji L.-Y,. Bai J., et al. Effects of the short-term application of pantopra-zole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-4. DOI: 10.3892/etm.2016.3693Wei P., Zhang Y.-G., Ling L., Tao Z.-Q,. Ji L.-Y,. Bai J., et al. Effects of the short-term application of pantopra-zole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-4. DOI: 10.3892/etm.2016.3693Jensen B.E.S., Hansen J.M., Larsen K.S., Junker A., Lassen J.F., Jensen S.E., et al. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. Eur J Gastroenterol. 2017;29(10):1118-25. DOI: 10.1097/MEG.0000000000000934Jensen B.E.S., Hansen J.M., Larsen K.S., Junker A., Lassen J.F., Jensen S.E., et al. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. Eur J Gastroenterol. 2017;29(10):1118-25. DOI: 10.1097/MEG.0000000000000934Farhat N., Haddad N., Crispo J., Birkett N., VcNair D., Momoli F., et al. Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016. Eur J Clin Pharmacol. 2019;75(2):227-35. DOI: 10.1007/s00228-018-2564-8Farhat N., Haddad N., Crispo J., Birkett N., VcNair D., Momoli F., et al. Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016. Eur J Clin Pharmacol. 2019;75(2):227-35. DOI: 10.1007/s00228-018-2564-8Moayyedi P., Eikelboom J.W., Bosch J., Conolly S.J., Dyal L., Shestakovska O., et al. Pantoprazole to prevеnt gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double blind, placebo-controlled trial. Gastroenterology. 2019;157(2):403-12. DOI: 10.1053/j.gastro.2019.04.041Moayyedi P., Eikelboom J.W., Bosch J., Conolly S.J., Dyal L., Shestakovska O., et al. Pantoprazole to prevеnt gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double blind, placebo-controlled trial. Gastroenterology. 2019;157(2):403-12. DOI: 10.1053/j.gastro.2019.04.041Lee B.E., Kim G.H., Song G.A., Seo J.H., Jeon J.Y., Baek D.H., Kim D.U. Continuos infusion versus intermittent dosing with pantoprazole for gastric endoscopic submucosal dissection. Gut Liver. 2019;13(1):40-7. DOI: 10.5009/gnl18222Lee B.E., Kim G.H., Song G.A., Seo J.H., Jeon J.Y., Baek D.H., Kim D.U. Continuos infusion versus intermittent dosing with pantoprazole for gastric endoscopic submucosal dissection. Gut Liver. 2019;13(1):40-7. DOI: 10.5009/gnl18222Jung S.W., Kim S.Y., Chor J.W., Hyun J.J., Jung K.Y., Koo J.S., et al. Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection. J Gastroenterol Hepatol. 2017;32(4):778-81. DOI: 10.1111/jgh.13597Jung S.W., Kim S.Y., Chor J.W., Hyun J.J., Jung K.Y., Koo J.S., et al. Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection. J Gastroenterol Hepatol. 2017;32(4):778-81. DOI: 10.1111/jgh.13597Гриневич В.Б., Губонина И.В., Дощицин В.Л., Котовская Ю.В. Кравчук Ю.А., Педь В.И., и др. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COV-ID-19). Кардиоваскулярная терапия и профилактика. 2020;19(4):2630.Grinevich V.B., Gubonina I.V., Doshchitsin V.L., Kotovskaya Yu.V., Kravchuk Yu.A., Ped V.I., et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630. (In Russ.) DOI:10.15829/1728-8800-2020-2630DOI:10.15829/1728-8800-2020-2630Moayyedi P., Eikelboom J.W., Bosch J., Conolly S.J., Dyal L., Shestakovska O., et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients recriving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682-91. DOI: 10.1053/j.gastro.2019.05.056Moayyedi P., Eikelboom J.W., Bosch J., Conolly S.J., Dyal L., Shestakovska O., et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients recriving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682-91. DOI: 10.1053/j.gastro.2019.05.056Schneider J.L., Kolitsopoulos F., Corley D.A. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(1):73-82. DOI: 10.1111/apt.13450Schneider J.L., Kolitsopoulos F., Corley D.A. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(1):73-82. DOI: 10.1111/apt.13450Kuan Y.Ch., Huang K.W., Lin C.J., Luo J.C., Kao C.H. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis. Clin Med. 2019; 8(8):1108. DOI:10.3390/jcm8081108Kuan Y.Ch., Huang K.W., Lin C.J., Luo J.C., Kao C.H. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis. Clin Med. 2019; 8(8):1108. DOI:10.3390/jcm8081108Brunner G., Athmann C., Schneider A. Long-term, openlabel trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012;36(1):37-47. DOI: 10.1111/j.1365-2036.2012.05106.xBrunner G., Athmann C., Schneider A. Long-term, openlabel trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012;36(1):37-47. DOI: 10.1111/j.1365-2036.2012.05106.xYing J., Li L.-C., Wu C.-Y., Yu Z.-W., Kan L-D. The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China Rev Esp Enferm Dig. 2019;111(10):738-43. DOI: 10.17235/reed.2019.6155/2019Ying J., Li L.-C., Wu C.-Y., Yu Z.-W., Kan L-D. The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China Rev Esp Enferm Dig. 2019;111(10):738-43. DOI: 10.17235/reed.2019.6155/2019Matuz M., Benko R., Engi Z., Schvab K., Doro P., Viola R., et al. Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics. Front Pharmacol. 2020;11:552102. DOI: 10.3389/fphar.2020.552102Matuz M., Benko R., Engi Z., Schvab K., Doro P., Viola R., et al. Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics. Front Pharmacol. 2020;11:552102. DOI: 10.3389/fphar.2020.552102Matuz M., Benko R., Engi Z., Schvab K., Doro P., Viola R., et al. Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics. Front Pharmacol. 2020;11:552102. DOI: 10.3389/fphar.2020.552102

The authors declare that there are no conflicts of interest present.